Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Phase 2

Active, not recruiting

Conditions: Metastatic Melanoma

Interventions: Drug: ipilimumab
Drug: nivolumab

First Posted Date: 2017-04-20

Last Posted Date: 2024-05-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 70

Registration Number: NCT03122522

Locations: 🇺🇸
JOHNS HOPKINS HOSPITAL (Data Analysis Only), Baltimore, Maryland, United States
🇺🇸
Columbia University (Data Analysis Only), New York, New York, United States
🇺🇸
Brigham and Women's Hospital (Data and Specimen Analysis Only), Boston, Massachusetts, United States

and more 11 locations

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: durvalumab
Drug: tremelimumab
Radiation: Radiotherapy (RT)
Procedure: ablation

First Posted Date: 2017-04-20

Last Posted Date: 2022-07-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT03122509

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Phase 1

Completed

Conditions: Metastatic Anaplastic Thyroid Cancer

Interventions: Drug: durvalumab
Drug: tremelimumab
Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2017-04-20

Last Posted Date: 2022-06-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT03122496

Locations: 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering @ Rockville, Rockville Centre, New York, United States

and more 5 locations

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Drug: Atezolizumab

First Posted Date: 2017-04-19

Last Posted Date: 2019-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03120676

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

and more 3 locations

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

Phase 3

Completed

Conditions: Surgery

Interventions: Drug: Neostigmine+glycopyrrolate
Drug: Sugammadex

First Posted Date: 2017-04-17

Last Posted Date: 2023-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 201

Registration Number: NCT03116997

Locations: 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Westchester, Harrison, New York, United States

and more 1 locations

Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

Terminated

Conditions: Healthy

Interventions: Other: Leukapheresis

First Posted Date: 2017-04-14

Last Posted Date: 2021-02-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT03114566

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Imaging With a New Agent That Finds a Cancer Protein Called HER2

Phase 1

Completed

Conditions: HER2-positive Carcinoma
HER2-positive Primary Malignancy

Interventions: Drug: Zr-DFO-pertuzumab PET/CT

First Posted Date: 2017-04-12

Last Posted Date: 2018-04-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT03109977

Locations: 🇺🇸
Memorial Slaon-Kettering Cancer Center, New York, New York, United States

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

Phase 1

Active, not recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Procedure: Hepatic artery embolization (HAE)
Drug: Bumetanide

First Posted Date: 2017-04-11

Last Posted Date: 2024-04-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03107416

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (Consent and follow-up only), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and follow-up only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown, New Jersey, United States

and more 2 locations

Adaptive Radiotherapy for Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer
Paranasal Sinus Cancer
Nasopharynx Cancer
Hypopharynx Cancer
Oropharynx Cancer
Oral Cavity Cancer
Larynx Cancer

Interventions: Radiation: Adaptive Radiotherapy

First Posted Date: 2017-03-30

Last Posted Date: 2021-10-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT03096808

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma
Locally Advanced
Unresectable

Interventions: Drug: Atezolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2017-03-28

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT03093922

Locations: 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy